Savara (SVRA) Cash from Operations (2010 - 2026)
Savara (SVRA) reported Cash from Operations of 33000000.0 for Q1 2026, down 21.37% year-over-year from 41970109.46 in Q1 2025, and down 31.7% quarter-over-quarter from 25057000.0 in Q4 2025.
Savara (SVRA) Cash from Operations (2010 - 2026) Analysis & Trends
Savara (SVRA) has 17 years of Cash from Operations data on file, last reported at 33000000.0 in Q1 2026.
- Cash from Operations for Q1 2026 came in at 33000000.0, down 21.37% year-over-year; the trailing twelve-month figure through Mar 2026 was 106848000.0 (down 11.73% YoY), and the FY2025 annual result was 101037000.0, down 13.41% from the prior year.
- Cash from Operations eased to 33000000.0 in Q1 2026 per SVRA's latest filing, from 25057000.0 in the prior quarter.
- Over five years, Cash from Operations peaked at 8162000.0 in Q3 2022 and troughed at 33000000.0 in Q1 2026.
- A 5-year average of 18161176.47 and a median of 20644000.0 in 2024 frame the typical range for Cash from Operations.
- The sharpest annual moves came in 2022 and 2024: Cash from Operations increased 23.6% in 2022, then slumped 118.99% in 2024.
- A 5-year view of Cash from Operations shows it stood at 8651000.0 in 2022, then slumped by 80.36% to 15603000.0 in 2023, then plunged by 49.21% to 23281000.0 in 2024, then dropped by 7.63% to 25057000.0 in 2025, then slumped by 31.7% to 33000000.0 in 2026.
- Business Quant data shows SVRA's Cash from Operations at 33000000.0 in Q1 2026, 25057000.0 in Q4 2025, and 22530000.0 in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash from Operations (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 814,307.08 Bn | 814,307.05 Bn | - | - |
| 2 | Belite Bio | 55,320.00 Bn | 55,320.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,149.72 Bn | 17,149.72 Bn | - | -1.67 Mn |
| 4 | Legend Biotech | 3,590.00 Bn | 3,589.71 Bn | 242.10 Mn | -12.20 Mn |
| 5 | Akari Therapeutics | 1,650.72 Bn | 1,650.72 Bn | - | -2.49 Mn |
| 6 | Evaxion A | 1,522.09 Bn | 1,522.07 Bn | - | - |
| 7 | Psyence Biomedical | 229.39 Bn | 229.38 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 113.09 Bn | 105.85 Bn | 2.59 Bn | 1.43 Bn |
| 9 | Abivax | 90.15 Bn | 90.15 Bn | - | - |
| 10 | Savara | 1.33 Bn | 1.33 Bn | - | -33.00 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -33.00 Mn |
| Mar 31, 2026 | -33.00 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Dec 31, 2025 | -25.06 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Sep 30, 2025 | -22.53 Mn |
| Jun 30, 2025 | -26.26 Mn |
| Jun 30, 2025 | -26.26 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Mar 31, 2025 | -27.19 Mn |
| Dec 31, 2024 | -23.28 Mn |
| Dec 31, 2024 | -23.28 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Sep 30, 2024 | -22.67 Mn |
| Jun 30, 2024 | -22.50 Mn |
| Jun 30, 2024 | -22.50 Mn |
| Mar 31, 2024 | -20.64 Mn |
| Mar 31, 2024 | -20.64 Mn |
| Dec 31, 2023 | -15.60 Mn |
| Dec 31, 2023 | -15.60 Mn |